125 related articles for article (PubMed ID: 36484851)
21. Cervical intraepithelial neoplasia in non-16/18 high-risk human papilloma virus positive/cytology negative women: An alternative approach in poor resource areas.
Yarandi F; Shirali E; Feizabad E; Ramhormoziyan S; Sarmadi S; SadrAmeli M; Arshadi E
Taiwan J Obstet Gynecol; 2023 Mar; 62(2):299-303. PubMed ID: 36965899
[TBL] [Abstract][Full Text] [Related]
22. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
23. Relationship between vaginal microecological changes and oncogene E6/E7 and high-risk human papillomavirus infection.
Huang J; Yin C; Wang J
J Obstet Gynaecol; 2023 Dec; 43(1):2161349. PubMed ID: 36645341
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic performance of HPV E6/E7 mRNA assay for detection of cervical high-grade intraepithelial neoplasia and cancer among women with ASCUS Papanicolaou smears.
Ren C; Zhu Y; Yang L; Zhang X; Liu L; Ren C
Arch Gynecol Obstet; 2018 Feb; 297(2):425-432. PubMed ID: 29143102
[TBL] [Abstract][Full Text] [Related]
26. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
[TBL] [Abstract][Full Text] [Related]
27. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
28. [Natural changes of high-risk HPV in women with negative for intraepithelial lesion or malignancy: a prospective 1 year study].
He Y; Wu YM; Yin CH; Geng YN; Yang SL; Kang LD
Zhonghua Fu Chan Ke Za Zhi; 2017 Nov; 52(11):740-744. PubMed ID: 29179268
[No Abstract] [Full Text] [Related]
29. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Anal Cytology in Women with History of Abnormal Pap Smear, Cervical Intraepithelial Neoplasia, Cervical Cancer and High Risk HPV for Anogenital Dysplasia.
Hosseini MS; Khosravi D; Farzaneh F; Ebrahimi A; Arab M; Ashraf Ganjoie T; Jamdar F; Moridi A; Chehrazi M
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3071-3075. PubMed ID: 30485943
[TBL] [Abstract][Full Text] [Related]
31. Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less.
Pretorius RG; Peterson P; Azizi F; Burchette RJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1260-5. PubMed ID: 17074547
[TBL] [Abstract][Full Text] [Related]
32. High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing.
Alonso I; Torné A; Puig-Tintoré LM; Esteve R; Quinto L; Garcia S; Campo E; Pahisa J; Ordi J
Am J Obstet Gynecol; 2007 Oct; 197(4):359.e1-6. PubMed ID: 17714678
[TBL] [Abstract][Full Text] [Related]
33. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Human Papillomavirus Genotyping before and after Cervical Conization for Squamous Intraepithelial Lesion.
Iida Y; Sato S; Okawa M; Hikino K; Komatsu H; Kudoh A; Chikumi J; Oishi T; Harada T; Taniguchi F
Acta Cytol; 2023; 67(1):17-26. PubMed ID: 36310011
[TBL] [Abstract][Full Text] [Related]
35. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
36. [Wait-and-see policy versus loop excision after two consecutive Pap-2 cervical smears: over time less surgery and an equivalent outcome; no substantial contribution to be expected from the detection of high risk human papillomavirus].
Bekkers RL; Hanselaar AG; Melchers WJ; van Schaik JH; Boonstra H; Massuger LF
Ned Tijdschr Geneeskd; 2003 Feb; 147(7):302-6. PubMed ID: 12622008
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implication of high risk human papillomavirus E6 and E7 mRNA in patients with intraepithelial lesions of the cervix in relationship to age.
Frega A; Lorenzon L; Giovagnoli MR; De Sanctis L; Fabiano V; Lukic A; Moscarini M; Torrisi MR; French D
Int J Immunopathol Pharmacol; 2011; 24(2):461-70. PubMed ID: 21658320
[TBL] [Abstract][Full Text] [Related]
38. Correlation of High-Risk HPV Genotypes with Pap Test Findings: A Retrospective Study in Eastern Province, Saudi Arabia.
Kussaibi H; Al Dossary R; Ahmed A; Muammar A; Aljohani R
Acta Cytol; 2021; 65(1):48-55. PubMed ID: 32784299
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of HPV-16/18 genotypes and immediate histopathologic correlation results in a Chinese population with negative cytology and positive high-risk HPV testing.
Tao X; Zhang H; Li J; Zhang H; Xiao J; Zhang L; Zhou X; Sui L; Wang L; Zhao C
Cancer Cytopathol; 2019 Oct; 127(10):650-657. PubMed ID: 31532582
[TBL] [Abstract][Full Text] [Related]
40. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3.
Zielinski GD; Rozendaal L; Voorhorst FJ; Berkhof J; Snijders PJ; Risse EJ; Runsink AP; de Schipper FA; Meijer CJ
Gynecol Oncol; 2003 Oct; 91(1):67-73. PubMed ID: 14529664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
